This news article was originally written in Spanish. It has been automatically translated for your convenience. Reasonable efforts have been made to provide an accurate translation, however, no automated translation is perfect nor is it intended to replace a human translator. The original article in Spanish can be viewed at El sector biotecnológico se reúne para analizar nuevas estrategias de financiación

The sector biotecnológico gathers to analyse new strategies of financials

22/11/2010

November 22, 2010

The Catalan biotechnology sector continues a trend in growth above the average Spanish and European. But to consolidate this trend, the magic word is financing. In this context, the alternative investment market (aim) is emerging as one of key future strategies, and tools which is specially designed and oriented to companies expanding, as it is the case of the biotechnological.

On November 24, the employer CataloniaBio gathers in the Parc Científic de Barcelona representatives related to the sector and the funding with the objective of analysing, from an eminently practical perspective, what is the role of the MAB in a sector described as 'countercyclical', and also to discuss possible sectoral measures to address the current situation of economic crisis.

To this end, in addition to the President of the MAB, Antoni Giralt, also intervene Enrique Quemada, President of One to One; Rocío Fernández, Member of the PWC capital market; Silvia Sorribas, partner at the law firm Garrigues partners; Miquel Ángel Bonachera, Managing Director of AB-Biotics (the only biotechnology that is listed in the MAB from July 2010); and Asunción Soriano, Director of group Inforpress.